Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Promimic ABOSTO:PRO -1.98%68 3-Year EBITDA Growth Rate is 47.50% as of Mar. 2026, which is 36% above its 10-year median of 35.05. GuruFocus rates OSTO:PRO with a GF Score™ of 68/100 and a GF Value™ of kr32.32 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Promimic AB ranks better than 87.25% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 47.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 34.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Promimic AB was 47.50% per year. The lowest was -9.90% per year. And the median was 35.05% per year.
Promimic AB (OSTO:PRO) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Promimic AB 3-Year EBITDA Growth Rate Related Terms
OSTO:PRO vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Promimic AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Promimic AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Promimic AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Promimic AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 47.50% mean?
Promimic AB (OSTO:PRO) has a 3-Year EBITDA Growth Rate of 47.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Promimic AB and its competitors. This is 36% above median its historical median of 35.05. According to the industry distribution chart, Promimic AB ranks #88 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 12.8%.
Is Promimic AB's 3-Year EBITDA Growth Rate too high?
Promimic AB's current 3-Year EBITDA Growth Rate of 47.50% is 36% above median its 10-year median of 35.05. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Promimic AB's value of 47.50% is 479.3% above this industry median. Based on the distribution chart, Promimic AB ranks #88 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Promimic AB has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Promimic AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Promimic AB ranks #88 out of 690 companies for 3-Year EBITDA Growth Rate. This places Promimic AB in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Promimic AB's value of 47.50% is 479.3% above this benchmark. While the company's 10-year median is 35.05 vs. the industry median of 8.20, Promimic AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Promimic AB's current 3-Year EBITDA Growth Rate of 47.50% is 479.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Promimic AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Promimic AB's current 3-Year EBITDA Growth Rate is 47.50%, which is 36% above median its own 10-year median of 35.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Promimic AB stock overvalued right now?
Based on GuruFocus' analysis, Promimic AB (OSTO:PRO) is currently considered Significantly Undervalued. The stock's GF Value™ is kr32.32, compared to a current price of kr9.90 — trading 69.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 47.50%, which is 36% above median its 10-year median of 35.05 and 479.3% above the Medical Devices & Instruments industry median of 8.20. Promimic AB's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Promimic AB (OSTO:PRO), the current 3-Year EBITDA Growth Rate is 47.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Promimic AB (OSTO:PRO) Overvalued in 2026?
Based on GuruFocus' analysis, Promimic AB stock appears to be undervalued.
The current stock price of kr9.90 is trading 69.4% below its estimated GF Value™ of kr32.32.
GuruFocus considers Promimic AB to be Significantly Undervalued.
Key valuation signals for OSTO:PRO:
3-Year EBITDA Growth Rate: 47.50% (36% above median its 10-year median of 35.05)
GF Value™: kr32.32 vs. price of kr9.90 (69.4% below fair value)
Industry Position: 479.3% above the Medical Devices & Instruments median (#88 of 690)
No single metric tells the full story. See the OSTO:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PRO has been successfully added to your 
